TY - JOUR
AU - Yu, Luhai
AB - BackgroundAcute coronary syndrome (ACS) carries a high mortality in Uygur populations. Percutaneous coronary intervention (PCI) is a safe treatment for patients with ACS. Clopidogrel reduces the risk for recurrent cardiovascular events after PCI; however, its activity is influenced by cytochrome P450 (CYP450), ATP-binding cassette transporter B1 (ABCB1), and paraoxonase-1 (PON1).ObjectivesTo assess the effects of genetic polymorphisms CYP2C19*2, *3, *17, ABCB1 C3435T, and PON1 Q192R along with clinical and demographic factors on variations in responses in Uygur patients following PCI.MethodsWe enrolled 281 patients with PCI who were treated with clopidogrel and aspirin for at least 12 months and recorded major adverse cardiovascular events (MACE) or bleeding within 1 year. Approximately, 2 mL of peripheral venous blood samples were used for genotype detection. Binary logistic regression with likelihood ratio forward stepwise analysis and redundancy analysis were carried out to identify factors associated with MACE. We analyzed risk factors including age, body mass index, smoking, hypertension, dyslipidemia, gender, alcohol consumption, diabetes mellitus, carriers of ABCB1 C3435T T allele, carriers of PON1 Q192R A allele, metabolizer phenotype of CYP2C19, number of targeted vessels, and number of stents.ResultsThe CYP2C19 IMs (OR 3.546, 95% CI 1.972–6.375, P = 0.001), CYP2C19 PMs (OR 7.038, 95% CI 1.658–29.880, P = 0.008), and number of targeted vessels (OR 2.033, 95% CI 1.078–3.648, P = 0.026) were significantly associated with MACE.ConclusionThe CYP2C19 IMs, PMs, and the number of targeted vessels are essential factors associated with MACE risk in dual clopidogrel-treated Uygur population with ACS following PCI. These data provide valuable insights into the genetic polymorphisms affecting clopidogrel response among minority groups in China.
TI - The effects of polymorphisms in CYP2C19, ATP-binding cassette transporter B1, and paraoxonase-1 on clopidogrel treatment of Uygur patients following percutaneous coronary intervention
JF - European Journal of Clinical Pharmacology
DO - 10.1007/s00228-021-03176-z
DA - 2021-11-01
UR - https://www.deepdyve.com/lp/springer-journals/the-effects-of-polymorphisms-in-cyp2c19-atp-binding-cassette-kqG23GRIxZ
SP - 1679
EP - 1686
VL - 77
IS - 11
DP - DeepDyve
ER -